Details
Stereochemistry | RACEMIC |
Molecular Formula | C21H20FN3O6S |
Molecular Weight | 461.463 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1SC2=C(C(O)=O)C(=O)C3=CC(F)=C(C=C3N12)N4CCN(CC5=C(C)OC(=O)O5)CC4
InChI
InChIKey=PWNMXPDKBYZCOO-UHFFFAOYSA-N
InChI=1S/C21H20FN3O6S/c1-10-16(31-21(29)30-10)9-23-3-5-24(6-4-23)15-8-14-12(7-13(15)22)18(26)17(20(27)28)19-25(14)11(2)32-19/h7-8,11H,3-6,9H2,1-2H3,(H,27,28)
DescriptionSources: http://www.leespharm.com/file/product/Unidrox%20PIL%20HK%20ver%202012.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/16286954 | https://adisinsight.springer.com/drugs/800015025 | https://www.ncbi.nlm.nih.gov/pubmed/15456336Curator's Comment: description was created based on several sources, including
https://hal.archives-ouvertes.fr/hal-00679605/document
Sources: http://www.leespharm.com/file/product/Unidrox%20PIL%20HK%20ver%202012.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/16286954 | https://adisinsight.springer.com/drugs/800015025 | https://www.ncbi.nlm.nih.gov/pubmed/15456336
Curator's Comment: description was created based on several sources, including
https://hal.archives-ouvertes.fr/hal-00679605/document
Ulifloxacin is a fluoroquinolone with potent antibacterial activity against a broad spectrum of Gram-positive and -negative bacteria. Ulifloxacin is the active form of the prodrug prulifloxacin and shows a highly potent antipseudomonal activity. Ulifloxacin is generally more active in vitro than other fluoroquinolones against a variety of clinical isolates of Gram-negative bacteria, including community and nosocomial isolates of Escherichia coli, Klebsiella spp., Proteus, Providencia and Morganella spp., Moraxella catarrhalis and Haemophilus spp. The activity of ulifloxacin against Pseudomonas aeruginosa varies between countries. Gram-positive organisms, including meticillin- or oxacillin-susceptible Staphylococcus aureus, Enterococcus spp. and Italian community isolates of Streptococcus pneumoniae are susceptible to ulifloxacin. Activity against Spanish strains of S. pneumoniae is moderate.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12621742 |
|||
Target ID: CHEMBL2363076 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12621742 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unidrox Approved UseUnidrox is indicated in the treatment of infections caused by susceptible organisms, in the following conditions: acute uncomplicated lower urinary tract infections (simple cystitis); complicated lower urinary tract infections; acute exacerbation of chronic bronchitis. |
|||
Curative | Unidrox Approved UseUnidrox is indicated in the treatment of infections caused by susceptible organisms, in the following conditions: acute uncomplicated lower urinary tract infections (simple cystitis); complicated lower urinary tract infections; acute exacerbation of chronic bronchitis. |
|||
Curative | Quisnon Approved UseThe treatment of gastroenteritis, including infectious diarrheas. |
PubMed
Title | Date | PubMed |
---|---|---|
Involvement of multiple transport systems in the disposition of an active metabolite of a prodrug-type new quinolone antibiotic, prulifloxacin. | 2003 |
|
Prulifloxacin. | 2004 |
|
Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy. | 2004 Fall |
|
Pharmacologic characteristics of prulifloxacin. | 2006 |
|
Determination of the active metabolite of prulifloxacin in human plasma by liquid chromatography-tandem mass spectrometry. | 2006 Mar 7 |
|
Determination of ulifloxacin by terbium-sensitized fluorescence with second-order scattering and its applications. | 2007 Dec |
|
Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. | 2007 Oct |
|
Effects of fluoroquinolones on bacterial adhesion and on preformed biofilm of strains isolated from urinary double J stents. | 2008 Apr |
|
Determination of ulifloxacin, the active metabolite of prulifloxacin, in human plasma by a 96-well format solid-phase extraction and capillary zone electrophoresis. | 2008 Sep 1 |
|
Active uptake of ulifloxacin from plasma to lung that controls its concentration in epithelial lining fluid. | 2009 Jun |
Patents
Sample Use Guides
One 600 mg tablet is sufficient. For patients with complicated lower urinary tract infections or acute exacerbation of bronchitis - one 600 mg tablet once daily for up to a maximum of 10 days of treatment
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15456336
Activity of prulifloxacin against Gram-negative and -positive bacteria (MIC50) is 0.015-2 mg/L
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J01MA17
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
||
|
WHO-VATC |
QJ01MA17
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
||
|
NCI_THESAURUS |
C795
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000080843
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | |||
|
123447-62-1
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | |||
|
759833
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | |||
|
m9286
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
65947
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | |||
|
C72637
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | |||
|
J42298IESW
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | |||
|
DB11892
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | |||
|
2325
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | |||
|
7249
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | |||
|
DTXSID0046480
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | |||
|
C074191
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | |||
|
CHEMBL422648
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | |||
|
PRULIFLOXACIN
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY | |||
|
SUB10156MIG
Created by
admin on Fri Dec 15 16:01:53 GMT 2023 , Edited by admin on Fri Dec 15 16:01:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD